Everything below concerns lyophilized peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
=== June 2025 military parade and "No Kings" protests === On June 14, the Trump administration held the U.S. Army 250th Anniversary Parade in Washington, D.C., to celebrate the 250th anniversary of the U.S. Army. The parade is estimated to have cost somewhere between $25 and $45 million. In protest, 50501, Indivisible, and other organizations organized No Kings protests in many American cities. Millions attended what was then the largest protest since Trump was re-elected. Two follow up No Kings protests (also referred to as No Kings 2 and No Kings 3) took place across the United States and cities abroad in October 2025 and March 2026. The October protests took place in some 2,700 locations across the country, and drew an estimated 7 million attendees, The March 2026 protests, held in response to the killings of Alex Pretti and Renée Good, as well as the 2026 Minnesota general strike, drew even more participants. The organizers claim the No Kings 3 protests took place in 3,300 locations and drew an estimated eight to nine million protestors, which would make it the largest single-day protest in American history.
== Occurrence == Obsidian is found near volcanoes in locations which have undergone rhyolitic eruptions. It can be found in Argentina, Armenia, Azerbaijan, Australia, Canada, Chile, Georgia, Ecuador, El Salvador, Greece, Guatemala, Hungary, Iceland, Indonesia, Italy, Japan, Kenya, Mexico, New Zealand, Papua New Guinea, Peru, Russia, Scotland, the Canary Islands, Turkey and the United States. Obsidian flows which are so large that they can be hiked on are found within the calderas of Newberry Volcano (Big Obsidian Flow, 700 acres) and Medicine Lake Volcano in the Cascade Range of western North America, and at Inyo Craters east of the Sierra Nevada in California. Yellowstone National Park has a mountainside containing obsidian located between Mammoth Hot Springs and the Norris Geyser Basin, and deposits can be found in many other western U.S. states including Arizona, Colorado, New Mexico, Texas, Utah, and Washington, Oregon and Idaho.
=== Defining agrifood systems resilience === The resilience of agrifood systems builds on the concept of resilience, which originated in the study of ecosystems and evolved over 50 years into an object of study across an array of disciplines, including engineering, agriculture, economics and psychology. Although there is little agreement today as to a precise definition across disciplines, broadly speaking, resilience can be defined as the dynamic capacity to continue to achieve goals despite disturbances. In a call for cross-sectoral collaboration to prevent, anticipate, absorb, adapt and transform in the face of shocks and stresses across all sectors of society, the United Nations has developed and adopted the UN Common Guidance on Helping Build Resilient Societies. Since there is a wide variety of risks relating to understanding resilience, the UN offers the following definition: "the ability of individuals, households, communities, cities, institutions, systems and societies to prevent, anticipate, absorb, adapt, and transform positively, efficiently and effectively when faced with a wide range of risks, while maintaining an acceptable level of functioning and without compromising long-term prospects for sustainable development, peace and security, human rights and well-being for all." Resilience building is a system-wide multi-risk, multi-actor and multisectoral effort.
The capture and marking of birds enable detailed studies of life history. Techniques for capturing birds are varied and include the use of bird liming for perching birds, mist nets for woodland birds, cannon netting for open-area flocking birds, the bal-chatri trap for raptors, decoys and funnel traps for water birds.
Flavin reductase is a dimer made up of two subunits. Each subunit is similar. Flavin reductase P, FRP, was studied by Tanner, Lei, Tu and Krause and was discovered to have a structure made up of two subunits each containing a sandwich domain and an excursion domain. The excursion domains of each subunit reach out to connect the sandwich domain of the other subunit. This creates a large hydrophobic core in flavin reductase The enzyme has two binding sites, one for NADPH and one for the flavin mononucleotide substrate. The isoalloxazine ring of flavin mononucleotide is where reduction occurs. Therefore, this is where flavin creates a variety of hydrogen bonds to connect to the amino acid side chains of flavin reductase. Side chains 167–169 in FRP block the isoalloxazine ring in FAD from binding the enzyme, making FRP an FMN specific flavin reductase. The placement of methyl groups in the isoalloxazine ring can also have an effect on the binding and specificity of the enzyme for substrate. There is a depletion of a C-terminal extension that allows for the binding of NADPH, and studies show that if it is removed, it is depleted, catalytic activity increases.
Sources: en.wikipedia.org
transcriptional bursting The intermittent nature of transcription and translation mechanisms. Both processes occur in "bursts" or "pulses", with periods of gene activity separated by irregular intervals.
== Mitochondrial events controlling fuel selection == Fatty acids are preferentially oxidized because of the inactivation of PDH by fatty acid oxidation inhibiting glucose oxidation. This suggests that mitochondrial metabolism may control fuel selection. Cellular respiration is stimulated by fatty acids and this relates to an increase in the mitochondrial NADH to NAD+ ratio, suggesting that energy provision overtakes energy consumption. Switching from glucose to fatty acid oxidation leads to a bigger proportion of electrons being transported to complex 2 rather than complex 1 of the respiratory chain. This difference leads to a less efficient oxidative phosphorylation. By oxidizing fatty acids, mitochondria increase their respiration while increasing the production of ROS.
=== Ferroptosis === Ferroptosis is a form of regulated cell death characterized by the iron-dependent accumulation of lipid hydroperoxides to lethal levels. ALOX5-mediated ferroptosis acts as a cell death pathway upon oxidative stress in HD. Inhibitors of ferroptosis are protective in models of degenerative brain disorders, including Parkinson's, Huntington's, and Alzheimer's diseases.
====== Medication assisted treatment (MAT): Opioid agonist therapy (OAT) and Opioid substitution therapy (OST) ====== Medication assisted treatment (MAT) is the prescription of legal, prescribed opioids or other drugs, often long-acting, to diminish the use of illegal opioids. Many types of MAT exist, including opioid agonist therapy (OAT) where a safer opioid agonist is employed or opioid substitution therapy (OST) which employs partial opioid agonists. However, MAT, OAT, OST are often used synonymously. Opioid agonist therapy (OAT) involves the use of a full opioid agonist treatment like methadone and is generally taken daily at a clinic. Opioid substitution therapy (OST) involves the use of the partial agonist buprenorphine or a combination of buprenorphine/naloxone (brand name Suboxone). Oral/sublingual formulations of buprenorphine incorporate the opioid antagonist naloxone to prevent people from crushing the tablets and injecting them. Unlike methadone treatment, buprenorphine therapy can be prescribed month-to-month and obtained at a traditional pharmacy rather than a clinic. The driving principle behind OAT/OST is the program's capacity to facilitate a resumption of stability in the person's life, while they experience reduced symptoms of withdrawal symptoms and less intense drug cravings; however, a strong euphoric effect is not experienced as a result of the treatment drug. In some countries, such as Switzerland, Austria, and Slovenia, patients are treated with slow-release morphine when methadone is deemed inappropriate due to the individual's circumstances.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.